Horst Lindhofer

TL;DR: Intrapleural administration of catumaxomab is feasible although the substantial number of drop-outs and deaths in short proximity to study treatment raise questions whether MPE is the right indication for catumxomab or whether the patient population should be defined different.

TL;DR: Intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer and had an acceptable safety profile.

TL;DR: The induction of a T‐ cell‐activatory and melanoma cell‐inhibitory cytokine milieu together with the redirection of T‐cell‐ and accessory cell‐mediated cytotoxicity are interesting features of these trifunctional antibodies, which may be a new option for the therapy of human malignant melanoma.

TL;DR: In this article, the authors described a method for ex vivo immunization of humans and animals comprising the following steps of isolating autologous tumour cells, treating the tumor cells to prevent the survival thereof following reinfusion, and incubating the thus treated tumours with intact heterologous bispecific and/or trisepcific antibodies showing the following properties: α binding to a T cell; β binding to at least one antigen on a tumour cell; γ binding, by their Fc portion, or by a third specificity (in the case of tr

TL;DR: The induction of anti-tumor specific T-lymphocytes after intraperitoneal administration of trAb in patients with PC is described and the induction of long lasting tumor immunity after treatment with trAb is demonstrated.